AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06236997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Study NCT06236997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide, carboplatin(EC)
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Study NCT05651737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sui App (SRK)
Description: The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification
Study NCT05309889 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04379115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Active tDCS + Active TUS
Description: Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes.
Study NCT04379115 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham tDCS + Sham TUS
Description: Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT04783623 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical endometrioma excision
Description: We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
Study NCT05019547 — intervention group
Intervention type: BEHAVIORAL
Intervention: Determining Barriers and Facilitators of Physical Activity
Description: Determining Barriers and Facilitators of Physical Activity
Study NCT05000684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004 in combination with toripalimab
Description: Usage and dosage: Inject 200mg once every 3 weeks
Study NCT05638672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashi Baidu Granule
Description: Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
Study NCT05638672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monapiravir
Description: Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
Study NCT05342441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QT graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar.
Study NCT05342441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST/Gr graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar.
Study NCT05342441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BPTB graft
Description: Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar.
Study NCT06189781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.
Study NCT06189781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, lidocaine, ropivacaine
Description: The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
Study NCT06479486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assigned Interventions
Description: warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
Study NCT05088460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4461
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study NCT05089708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene Cream
Description: Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
Study NCT05089708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifarotene Vehicle Cream
Description: Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
Study NCT02866266 — intervention group
Intervention type: OTHER
Intervention: Retrospective database review
Study NCT06006078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Patient Facemask
Description: A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
Study NCT05088460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Study NCT05434546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone
Description: Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
Study NCT06392815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cu DOTATATE PET
Description: The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
Study NCT06247826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
Study NCT05051618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER-MS
Description: The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level.
Study NCT05051618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FLEX-MS
Description: The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
Study NCT05356793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH-1
Description: Novel anti-infective eyedrop
Study NCT05356793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SCH-1 vehicle minus active components eyedrop
Study NCT05087303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Types of Telemedicine Delivery Models
Description: Each arm delivers standard sickle cell care using a different model based on patient location.
Study NCT05675150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Arts-Based Intervention
Description: The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflection and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in intervention may seek meaning, clarity, insight and healing.
Study NCT05636215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI354
Description: Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
Study NCT05383807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warna-Warni Waktu
Description: Six videos and eighteen reinforcer activities
Study NCT06272682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic bethametasone injection
Description: betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
Study NCT06272682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local bethametasone injection
Description: Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
Study NCT05079438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendrobium Huoshanense Suppository
Description: 1.7g rectal administration per day for 5 weeks
Study NCT04970706 — intervention group
Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
Study NCT05596981 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study NCT05617872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinegar 20ml
Description: Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
Study NCT05617872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
Study NCT05617872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinegar 40ml
Description: Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
Study NCT06219577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systane Complete Multi-Dose PF
Description: Eyedrop
Study NCT06219577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Walgreen's Lubricant Balance
Description: Eyedrop
Study NCT06223932 — intervention group
Intervention type: DRUG
Intervention: Molnupiravir
Description: COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
Study NCT05011695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
Study NCT05430776 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobimodulation
Description: laser therapy application
Study NCT05430776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobimodulation
Description: laser therapy application
Study NCT05053763 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remimazolam
Description: The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
Study NCT05103592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tartrate- resistant Acid Phosphatase marker
Description: marker could be diagnostic for osteoporosis
Study NCT04739475 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non Surgical Periodontal Therapy
Description: Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study NCT06380608 — intervention group
Intervention type: PROCEDURE
Intervention: Local anesthesia
Description: Patients who will undergo a dental surgery under local anesthesia
Study NCT06380608 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Patients who will undergo a dental surgery under general anesthesia
Study NCT05535062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
Study NCT04731116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral Cannabidiol 150 mg twice daily during 14 days
Study NCT05223322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking Charge during Treatment (TCT) Intervention
Description: CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
Study NCT04904718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
Study NCT05418647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate Na
Description: high dialysate sodium (Na = 141 mmol/L) for 8 weeks
Study NCT05418647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dialysate Na
Description: low dialysate sodium (Na = 136 mmol/L) for 8 weeks
Study NCT05025345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Eyhance
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study NCT05025345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis 1 piece IOL
Description: Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study NCT05669313 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban 15 MG
Description: Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
Study NCT05378152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pipelle biopsy catheter
Description: A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
Study NCT05378152 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: A speculum is inserted into the vagina and then removed
Study NCT05257187 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcervical foley catheter
Description: The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
Study NCT05257187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter
Description: The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
Study NCT05802485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection of blood and tumor samples
Description: The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities.
Study NCT05430295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients